R-CHOP (lymphoma chemoimmunotherapy)
The standard first treatment for diffuse large B-cell lymphoma: rituximab (an antibody against CD20) plus four chemotherapy drugs (cyclophosphamide, doxorubicin, vincristine, prednisone), given every three weeks for six cycles. It cures about 60% of patients.
CHOP dates from the 1970s; adding rituximab (2002) raised cure rates by about 15 percentage points. Pola-R-CHP swaps vincristine for polatuzumab vedotin and improved progression-free survival (POLARIX); PET-guided shortening to four cycles suffices for low-risk early-stage disease (FLYER). Patients who relapse within a year now go to CAR-T rather than salvage chemotherapy and autologous transplant; bispecific antibodies (glofitamab, epcoritamab) are moving into first line combinations. BR (bendamustine-rituximab) and R-CVP are gentler regimens for indolent lymphomas. 'Chemoimmunotherapy' in lymphoma means antibody plus chemotherapy, not checkpoint inhibitors.
Pages like this
not linked directly; found by shared links- Key paperPOLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma
Shares Vincristine, Rituximab, Doxorubicin, Diffuse large B-cell lymphoma.
- Key paperMURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia.
- TermInfusion reactions, hypersensitivity and extravasation
- TermCardiotoxicity (LVEF decline, cardiomyopathy)
Shares Anthracyclines (doxorubicin, epirubicin), Doxorubicin.
- TermLymphodepletion before CAR-T
Shares Bendamustine, Cyclophosphamide.
- TrialTRANSFORM
- PairingCaution: chemoimmunotherapy in del(17p)/TP53 CLL
Shares Rituximab, Chronic lymphocytic leukaemia.
- TermABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)
Shares Deauville score and PET-adapted therapy, Doxorubicin.